What happened
Granata Bio announced a $15 million Series A+ backed by existing strategic investors. The company said the financing would support its infertility-drug pipeline and the evaluation of additional reproductive-health assets.
Why it matters
Fertility innovation is often concentrated in clinic services and laboratory technology. Investment in therapeutic development broadens the category, but a financing event is only the beginning of the evidence path.
What to watch
Which assets enter clinical development, trial design and diversity, published efficacy and safety data, and whether new products improve access as well as choice.
